Sign In
Buy NTLA
$13.02
-0.110 (-0.84%)
At Close: Jun 03, 2026
Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
07:30am, Wednesday, 07'th Jan 2026
CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera
Intellia Stock Declines Around 55% in 3 Months: Here's Why
12:01pm, Monday, 05'th Jan 2026
NTLA shares plunge 55% in three months after the FDA placed a clinical hold on Nex-Z, suspending trials and milestone guidance following the death of a patient.
Cathie Wood Doubles Down on Biotech as 2025 Ends, Offloads Rocket Lab
06:26am, Wednesday, 31'st Dec 2025
Cathie Wood's ARK Invest made a series of end-of-year portfolio adjustments on the second final trading day of 2025, tilting further toward biotechnology while
2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street
09:30am, Monday, 29'th Dec 2025
A clinical hold and a complex commercial path make Intellia Therapeutics' outlook uncertain. Despite steadily growing revenue, Iovance Biotherapeutics faces nearly insurmountable challenges.
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 05'th Dec 2025
CAMBRIDGE, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera
Geode Capital Management LLC Boosts Holdings in Intellia Therapeutics, Inc. $NTLA
04:00am, Saturday, 29'th Nov 2025
Geode Capital Management LLC lifted its stake in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) by 5.1% during the undefined quarter, according to the company in its most recent 13F filing with
Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry?
11:01am, Friday, 28'th Nov 2025
Intellia advances in vivo pipeline with lonvo-z through its pivotal HAELO study, eyeing mid-2026 data and a potential 2026 filing to propel growth.
BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential?
09:15am, Thursday, 27'th Nov 2025
Beam's broad early-stage pipeline and recent study progress take center stage as investors weigh its potential against rival NTLA's prospects.
AXQ Capital LP Buys New Position in Intellia Therapeutics, Inc. $NTLA
03:34am, Tuesday, 25'th Nov 2025
AXQ Capital LP acquired a new position in Intellia Therapeutics, Inc. (NASDAQ: NTLA) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The
What Moved Markets This Week
06:50am, Saturday, 22'nd Nov 2025
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock?
11:20am, Friday, 21'st Nov 2025
Intellia sinks 67% in a month after a clinical hold on nex-z and mixed third-quarter results, raising questions about its pipeline outlook and near-term direction.
2 Beaten-Down Stocks to Avoid Right Now
09:35am, Saturday, 15'th Nov 2025
Intellia Therapeutics and Sarepta Therapeutics have hit serious setbacks potentially linked to their treatments. Both biotechs have lost market value as a result, but both still seem too risky to cons
Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks?
10:01am, Friday, 14'th Nov 2025
Intellia faces FDA clinical holds on key ATTR studies as it readies crucial HAE data in 2026, making lonvo-z pivotal for its near-term outlook.
CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera
Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
05:13pm, Saturday, 08'th Nov 2025
CAMBRIDGE, Mass., Nov. 08, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ther
